American Express, Gilead Sciences And This US Oil Giant On CNBC's 'Final Trades'

On CNBC’s "Halftime Report Final Trades," Rob Sechan of New Edge Capital Group said Gilead Sciences, Inc. GILD is a very defensive, steady growth play. "It is cheap, cheap, cheap," he added.

Gilead Sciences reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and oncology. "Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy," said Daniel O'Day, Gilead's chairman & CEO.

Jason Snipe of Odyssey Capital Advisors said he likes American Express Company AXP. The stock has been little volatile over the last few weeks, following downbeat quarterly earnings, but volume was up 16%.

American Express reported Q1 revenue (net of interest expense) growth of 22% year-on-year to $14.28 billion, exceeding the consensus of $14.03 billion. EPS of $2.40 missed the consensus of $2.65.

Stephanie Link of Hightower said Chevron Corporation CVX is down 15% from its high level.

Chevron reported first-quarter FY23 sales of $50.79 billion, a decline of 6.6% year-over-year, beating the consensus of $47.98 billion.

Price Action: Chevron shares gained 2.6% to settle at $160.21, while American Express added 2.6% to $152.65 on Friday. Gilead Sciences shares rose 1.6% to close at $79.75 on Friday.
Check This Out: Top 5 Consumer Stocks That May Rocket Higher This Month

Photo via Pixabay.